Inpatient Parkinson’s Care: Challenges and Special Considerations

Jeryl Ritzi T. Yu

Apr 2023 DOI 10.35460/2546-1621.2023-0032

Why do we care?

The hospital is often a haven for people in need of care. However, for people with Parkinson’s disease (PD), hospitalizations can turn into a nightmare. In one study, 33% of people with PD experienced one or more complications, 25% received incorrect anti-Parkinson’s medications and 21% experienced deterioration of motor symptoms.[1]

 

People with PD are admitted to the hospital more frequently than those without PD[2], with as high as 34% hospitalization rate per year and a longer average length of stay compared to non-PD patients.[3,4] Only 15% of hospitalizations are directly related to PD complications while the rest are for indirect disease-related morbidities such as pneumonia, fractures from falls, etc, and non-PD related causes including surgeries.[5–7] In addition, people with PD have significant comorbidities, and comorbid illnesses are related to an increased risk of hospitalization.[8,9]

 

Although PD progression is not abrupt, PD symptoms can be more severe temporarily when patients are ill. Infections, metabolic changes, exposure to anesthesia, changes in medication regimen or new medication changes are some common factors that may worsen PD symptoms during hospitalization. More importantly, the inherent complexity of PD pathophysiology creates challenges in management. Therefore, understanding PD pathophysiology and recognizing care gaps enable optimization of inpatient care among this vulnerable population.

 

What can go wrong?

Complications may arise from multiple aspects of care. Broadly, these include medication administration, diet status and progression, management of agitation and psychosis, mobilization strategies, and perioperative considerations.

 

Levodopa administration is time critical.

Accuracy of medication administration times in the hospital is extremely vital in preventing deterioration. Levodopa, the most efficacious medication for PD for over 50 years now[10], has a short half-life and requires multiple times a day dosing.[11] With longer dosing intervals, problems related to wearing off arise. These include mobility problems, falls, worsening of tremor, dystonia, dysphagia, freezing of gait and other nonmotor symptoms, including shortness of breath and anxiety. On the other hand, dosing too early may cause dyskinesias, which predisposes patients to falls, inability to participate in therapy, psychosis, orthostasis and syncope.[12,13] For these reasons, management of PD medication regimen is a crucial aspect of inpatient care.

 

The multifactorial nature of deviations is well recognized. The staff's unawareness of time critical nature of PD medication administration, unavailability of medications, high patient-to-nurse ratio, and nothing per orem (NPO) status are some factors that prevent accurate administration of medications. Inaccuracies in medication administration occur at alarming rates; up to half with missing doses[14] and administrations occurring 30 minutes later from order times in 51% of doses and one hour later than order times in 30% of doses.[15]

 

Furthermore, people with PD have individualized outpatient regimens with varying doses, formulations and time intervals that are tailored to their symptoms throughout the day. One significant source of error is orders written as “qd,” “bid,” and “tid,” to suit hospital schedules, which are inappropriate for time-dependent dopaminergic PD medications and are often deviant from the patient’s home regimen.[12] We examined deviation rates between hospital administration times and the patient’s home regimen[16] and found that 47% had an average hospital dose timing interval that differed from outpatient timing interval by greater than 30 minutes. Admissions where at least one day included a 30-minute or greater deviation in the dosing interval had a longer length of stay (median 4.6 days vs 2.0 days). Delays in administration of inpatient orders and when compared to outpatient regimens have demonstrated poor outcomes, emphasizing the need for strict adherence to patients’ individualized outpatient medication regimens.

 

PD medication regimens are varied and complex.

Levodopa formulations are varied and complex with different pharmacokinetic and pharmacodynamic properties by formulation.[11,17] For example, carbidopa/levodopa immediate release (IR) when combined with entacapone has the same half-life but takes longer to absorb and has a 30% higher levodopa equivalent daily dose. Of note, entacapone should be administered concomitantly with levodopa for its effect of increased and more sustained plasma levodopa concentrations. Another formulation, carbidopa-levodopa controlled release (CR) has a bioavailability of 70% of IR with a maximum serum concentration of 30%, thereby requiring individual doses to be as high as three times IR doses to achieve the same plasma levels.[17] Aside from variations in levodopa, patients are on a wide variety of PD medications including dopamine receptor agonists, catechol-O-methyltransferase (COMT) inhibitors, adenosine 2A receptor antagonists, anticholinergics and other medications used to treat non-motor symptoms including those for psychosis, orthostatic hypotension, etc. Each medication has a different levodopa equivalent daily dose[18,19], which makes conversion from one to the other error prone, especially for clinicians relatively inexperienced with PD care.

 

Certain medications are contraindicated due to PD pathophysiology.

Another common issue is that contraindicated medications are often given when patients decompensate, which further worsens motor function, resulting in immobility and falls. An acutely agitated patient may be given haloperidol, or a nauseated patient may be given metoclopramide. Due to the fundamental PD pathophysiology involving loss of dopaminergic cells, it is important to take note of medications that affect dopaminergic states. Relatively commonly encountered medications with dopamine receptor blocking properties include antipsychotic drug classes (haloperidol, fluphenazine, chlorpromazine, risperidone, olanzapine, ziprazisone, aripiprazole, etc.) and antiemetic drug classes (metoclopramide, promethazine, prochlorperazine, etc).

 

Administration of contraindicated medications in PD patients experiencing delirium has been associated with increased lengths of stay compared to individuals without PD.[20] These further worsen mobility, cognition and swallowing [4,12,21] resulting in extended hospital stays and increased fatalities.[16,22,23] Medication selection is critical when managing behavioral issues to avoid worsening motor function and medical complications.

 

Patients with PD are at an increased risk of mental status changes in-hospital.

People with PD have as high as a five-fold risk of experiencing delirium or psychosis in the hospital.[24] Manifestations are variable, including confusion, hallucinations, agitation and hypomania[25], and underlying etiologies are multifactorial. Patients are being managed for acute and active conditions such as metabolic derangements, infections, or surgical procedures, which predisposes them to mental status changes secondary to systemic illnesses or exposure to new medications including certain classes of antibiotics and anesthetic agents. Among patients undergoing surgical procedures, as high as 60% of patients with PD experienced acute postoperative confusion lasting an average of 2.5 days with the relative risk between 2.8% to 8.1%.[26]

 

The hospital is also an unfamiliar environment with continuous monitoring that often disrupts patients’ circadian rhythm. These create challenges for patients with PD who thrive on familiarity and routine. Lastly, patients may have baseline cognitive impairment prior to hospitalization. This lowers the threshold for mental status changes in an unfamiliar environment when compounded by active metabolic derangements, infectious/inflammatory processes and/or exposure to new medications.

 

Patients with PD are at an increased risk for falls.

Hospitalized patients are at an increased risk for falls.[27] This risk is even higher in patients with PD due to several factors aside from their baseline motor impairment or gait instability. Orthostatic hypotension is experienced by up to 40% of patients with PD[28] which increases the risk for falls, morbidity and mortality.[29] This can be aggravated by dehydration or discontinuation of medications for orthostatic hypotension when supine hypertension is encountered by relatively inexperienced clinicians. Nocturnal urinary frequency is also common. The need to void during times of the day when lighting may be poor or when assistance is unavailable predisposes them to falls. Staffing constraints were found to be associated with increased risk of falls.[30] Another important aspect to consider is polypharmacy or the use of new medications including sedatives or antihistamines.[31] The use of antidopaminergic medications has been shown to increase falls with an odds ratio of 5.0[32], which in turn reduces patients’ ability to participate in rehabilitation, and thereby increasing the length of stay.[33]

 

Prolonged NPO status results in complications.

Given that carbidopa/levodopa is dosed several times per day due to its short half-life, problems arise when patients are placed on NPO for a longer period than necessary. A study on perioperative medication withholding found that levodopa median withholding time was 12.35 hours[34], equivalent to 2-4 doses missed depending on patient profile. Another reason a patient may be placed on NPO includes nausea, often without proper dysphagia screening or consultation with a speech language pathologist (SLP). As emphasized, missed doses predispose patients to mobility problems, falls, worsening of tremor, dystonia, dysphagia, freezing of gait and other non-motor symptoms, including shortness of breath and anxiety. Due to consequences with missed doses, circumstances that preclude patients from receiving their medications call for special considerations, which are discussed below.

 

Certain factors increase their risk for infections.

Patients with PD often experience sialorrhea and may have silent aspiration which increases risk of respiratory infections,[35] emphasizing the need for proactive interventions in this population. Despite pervasive swallowing problems in PD[36], swallow evaluations were performed in only 25% of cases and only 1/8 of patients had swallowing evaluations performed prior to an aspiration event.[37] Increased risk of aspiration can be further aggravated by being placed on prolonged NPO or with prolonged duration of intubation. Considering their baseline swallowing problems, screening and monitoring of swallowing problems should be the standard of care in this population.

 

Perioperative management of PD presents unique scenarios.

A considerable proportion of people with PD are admitted for emergent or elective surgeries. Perioperative states often predispose this vulnerable population to critical care gaps, which often result in post-procedural deterioration and complications.[38] Patients with sialorrhea and dystonic neck posturing may present challenges in airway management. Dysautonomia and neurogenic orthostatic hypotension is experienced by up to 40% of patients[28] with possible arterial hypertension when supine,[39,40] giving rise to fluctuations in blood pressure control intraoperatively. Patients are also predisposed to medication interactions, particularly those with QT prolongation effects in the setting of concomitant general anesthesia (antiemetics such as ondansetron, antipsychotics such as quetiapine, antidepressants such as citalopram). In cases of postoperative nausea and agitation, a patient is commonly either placed on NPO or given medications with antidopaminergic properties, which further worsen motor function. Mobilization post-surgery is also critical to prevent further deterioration of motor function. Lastly, surgical devices such as deep brain stimulation (DBS) leads and implantable pulse generators (IPG) warrant preoperative preparations.

 

How do we optimize inpatient care?

Given what we know about the fragility of people with PD when hospitalized, identifying controllable risk factors and minimizing the impact for this population is paramount. An ideal strategy utilizes a three-pronged approach involving education, technology and proactive intervention utilizing specialists as part of a multifaceted approach.

 

Medication administration

As individuals with PD are admitted for a myriad of reasons other than PD-related issues, they receive care from units other than those specialized in neurologic care. Therefore, there is a need to educate all providers on complexity of PD medications, emphasizing the need for timeliness of administration and avoidance of substitutions and contraindicated medications. Nursing education and other measures including pharmacist review of medications and improved stocking of medications have reduced length of hospital stay and improved medication administration.[13,41,42]

 

Technology can also enable facilitation of medication administration and avoidance of contraindicated medications. The use of medication order constraints which forces custom hour/minute time orders, drug-disease interactions and missed dose timing alerts, are reminders for all healthcare providers and may be particularly helpful for those relatively inexperienced in PD inpatient care. A full list of medications to be avoided or used in caution among patients with PD can be found in the American Parkinson Disease Association page.[43] Electronic medical record alerts and in-service didactic training sessions for nurses and physicians have indeed been shown to significantly reduce prescribing of contraindicated medications.[42] Along these lines, the clinical pharmacist’s role is extremely vital, especially among institutions without the electronic medical record system. Another strategy is to utilize active interventions to improve PD care. Similar to stroke care, it has been suggested that involving PD specialists or advanced practice nurses can improve a patient’s hospitalization experience.[44,45] A specialized PD unit where the nursing staff is specifically trained in the care of PD has been shown to result in reduced medication delays, shorter length of stay and fewer episodes of acute delirium.[46] In hospitals where a specialized PD unit may not be feasible, active intervention via PD consultation services is an option. This involves having a physician or nurse trained in PD care as a resource for concerns surrounding special circumstances other staff may be unfamiliar with. In relation to medication availability, it is a common practice for hospital pharmacies to practice judicious selection of specific medications to be stocked. At a minimum, IR carbidopa/levodopa should be stocked with efforts to ensure a supply of at least 24 hours when a patient is admitted. When other levodopa formulations are unavailable, consider using medications from the patient’s personal supply, until such a time when the specific formulation is available. As a last resort, levodopa equivalent doses can be calculated with the guidance of a therapeutic exchange protocol.[18,47] The goal, however, is to avoid substitutions unless absolutely necessary, and to maintain all patients on their outpatient regimen as closely as possible (within 15 minutes of outpatient schedule, 100% of the time) unless there is convincing evidence that a recent change in the regimen has created a change in symptoms that have led to hospitalization.

 

Diet status and progression, speech and swallow

Unnecessary NPO status should be avoided. If NPO status is to be initiated related to swallowing problems that were identified, it is prudent to refer to an SLP for swallowing evaluation prior to placing a patient on NPO. For procedures other than major gastrointestinal surgeries, NPO status should be classified as NPO except for PD medications. Strict NPO including medications status should be reserved only for major gastrointestinal surgeries. If strict NPO status is necessary, alternative routes of administration such as nasogastric tube if without contraindications or alternative formulations should be considered when appropriate for the patient. Options depending on availability include disintegrating via sublingual, inhaled levodopa, intestinal gel infusion through pump, rotigotine transdermal patch, or apomorphine sublingual, subcutaneous injection.

 

To minimize the risk for aspiration, a standard protocol for screening should be established to assess dysphagia risk. This should also include patients without known swallowing problems prior to admission as silent aspiration and sialorrhea may increase aspiration risks in this population.[35] Screening for dysphagia is to be done within 24 hours ideally, with measures taken to minimize the risk of aspiration pneumonia. Ideally, bedside nurses should be trained to complete bedside swallow screening for all patients with PD and to notify the team of abnormal results, which should prompt referral to SLP for further management. Measures to minimize the risk of aspiration should be in place. These include ensuring that patients are sitting upright in a chair instead of bed when eating or if confined to bed, ensuring that the head of bed is as upright as possible. Patients identified to be at high risk for aspiration based on SLP evaluation warrant closer supervision. Lastly, patients experiencing varying degrees of dysphagia should be placed on the appropriate regimen that prioritizes closest adherence to their home regimen. This entails consulting neurology when considering holding PD medications due to a concern for dysphagia.

 

Management of mental status changes

Mental status changes (agitation, delirum, psychosis, confusion, hallucinations) are often multifactorial in nature. As PD patients thrive on familiarity and routine, they need to be frequently reoriented to the hospital setting and time of the day. When there is no urgent need for monitoring, minimize nighttime sleep interruptions to allow the patient to rest as best as possible. Maintain a home regimen that worked well prior to admission and correct underlying problems such as metabolic disturbances. Carefully review medications to remove offending factors such as medications that could precipitate delirium. This may entail multidisciplinary management with services involved (eg, infectious disease discussion as certain antimicrobials may lower the threshold to develop mental status changes). When medications are necessary, consider using clozapine, quetiapine or pimavanserin based on best current evidence.[48] Classifications of mental status changes in PD are variable[25] and a consensus on management for acute agitation among patients with PD admitted in-hospital is yet to be established.

 

Mobilization strategies

Immobilization not only results in poor motor function, but also increases risk for deep venous thrombosis which was present among 5% of PD patients on outpatient workup.[49] Patients should not be confined to bed. Consider reinstating mobilization orders as tolerated and postoperatively when stable with fall precaution. Monitor mobilization of patients with gait problems, use toileting strategies for patients with incontinence, and adjust medications that may predispose patients to falls. Ensure adequate staffing and train allied care professionals (physical and occupational therapists) to allow timely and safe mobilization.

 

Management of orthostatic hypotension should be optimized as it can be a barrier to effective rehabilitation sessions. When orthostatic hypotension is present, pay careful attention to increases in dopaminergic medications. Consult with a neurologist when considering adjustments in dopaminergic medications. Avoid aggressive management of hypertension in a patient with neurogenic orthostatic hypotension. Hydrate adequately, use medications (midodrine, fludrocortisone, etc.) when appropriate, allow liberal salt in the diet, and elevate the head of bed.

 

Perioperative considerations

A multidisciplinary approach is warranted to avoid complications that may arise at multiple levels perioperatively. The admitting team, nurses and pharmacy should coordinate to ensure timely administration of medications. Surgeries should be scheduled earlier during the day if the patient is to be placed NPO overnight to minimize disruptions in PD medication regimen. Nuances of NPO and necessary planning before, during and after surgery should be developed through team training and standard perioperative care. Continue to take anti-PD medications with sips of water. Providers should be aware of dopamine agonist withdrawal syndrome manifesting as psychiatric and autonomic manifestations, which may sometimes be mistaken for symptoms of wearing off or mental status changes in hospital.[50]

 

Intraoperatively, the medical team should be aware of possible challenges that may arise in airway management, especially among patients with dystonic neck posturing and sialorrhea. A careful review of the patient’s non-motor symptoms is critical to determine any history of dysautonomia as this may give rise to fluctuations in blood pressure control intraoperatively. Fluid volume status and pain should be controlled adequately to prevent blood pressure fluctuations. For patients with PD, paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) are generally safe. Carefully review medications as PD patients may be on medications which may be associated with QT prolongation in the setting of concomitant general anesthesia.

 

For patients with a DBS device, the IPG should be switched off prior to the procedure and switched back on after the procedure. Electromagnetic interference with the IPG by electrical appliances used during surgery and resuscitation (eg, diathermy, electrocautery, external cardiac defibrillator) can alter stimulation and possibly result in IPG failure.[51–53]

 

Postoperatively, ensure resumption of PD medications when appropriate (ie, all surgeries other than major gastrointestinal surgery, etc). For patients who are nauseated, consider disintegrating levodopa formulation. Certain institutions utilize a standard postoperative order set intended for the general patient population. Take note of and exclude antidopaminergic medications for nausea and agitation. If an antiemetic is to be given, prefer ondansetron and domperidone instead of metoclopramide, promethazine and prochlorperazine. Finally, ensure early involvement of SLP/occupational therapy to prevent aspiration and physical therapy to prevent deconditioning.

 

Summary/Take Home Points

  • Individuals with PD are vulnerable during hospitalizations due to the underlying complexities of PD pathophysiology.
  • A detailed understanding of factors driving the risk for deterioration among hospitalized people with PD is necessary to guide development of targeted care delivery.
  • Management should involve ensuring accurate medication administration, avoidance of prolonged NPO, fall precaution, appropriate medications for mental status changes, early referral to allied care services, optimization of perioperative care, and timely management of acute changes of PD symptoms impacted by hospitalization.
  • An integrated care approach involving the patient, caregiver, primary physician, nurse, pharmacist, outpatient neurologist and anesthesiologist is vital in optimizing inpatient care.

 

  1. Gerlach OHH, Broen MPG, van Domburg PHMF, Vermeij AJ, Weber WEJ. Deterioration of Parkinson’s disease during hospitalization: survey of 684 patients. BMC Neurol [Internet]. 2012;12:13. Available from: http://dx.doi.org/10.1186/1471-2377-12-13
  2. Guttman M, Slaughter PM, Theriault M-E, DeBoer DP, Naylor CD. Burden of parkinsonism: a population-based study. Mov Disord [Internet]. 2003;18(3):313–9. Available from: http://dx.doi.org/10.1002/mds.10333
  3. Zeldenrust F, Lidstone S, Wu S, Okun MS, Cubillos F, Beck J, et al. Variations in hospitalization rates across Parkinson’s Foundation Centers of Excellence. Parkinsonism Relat Disord [Internet]. 2020 [cited 2023 Apr 12];81:123–8. Available from: https://www.prd-journal.com/article/S1353-8020(20)30720-3/fulltext
  4. Gerlach OHH, Winogrodzka A, Weber WEJ. Clinical problems in the hospitalized Parkinson’s disease patient: systematic review: The hospitalized Parkinson’s disease patient. Mov Disord [Internet]. 2011;26(2):197–208. Available from: http://dx.doi.org/10.1002/mds.23449 
  5. Nóbrega AC, Rodrigues B, Melo A. Is silent aspiration a risk factor for respiratory infection in Parkinson’s disease patients? Parkinsonism Relat Disord [Internet]. 2008 [cited 2023 Apr 12];14(8):646–8. Available from: https://www.prd-journal.com/article/S1353-8020(08)00031-X/fulltext
  6. Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson’s disease. Intern Med J [Internet]. 2006;36(8):524–6. Available from: http://dx.doi.org/10.1111/j.1445-5994.2006.01123.x
  7. Klein C, Prokhorov T, Miniovitz A, Dobronevsky E, Rabey JM. Admission of Parkinsonian patients to a neurological ward in a community hospital. J Neural Transm (Vienna) [Internet]. 2009;116(11):1509–12. Available from: http://dx.doi.org/10.1007/s00702-009-0302-1
  8. Low V, Ben-Shlomo Y, Coward E, Fletcher S, Walker R, Clarke CE. Measuring the burden and mortality of hospitalisation in Parkinson’s disease: A cross-sectional analysis of the English hospital episodes statistics database 2009-2013. Parkinsonism Relat Disord [Internet]. 2015 [cited 2023 Apr 12];21(5):449–54. Available from: https://www.prd-journal.com/article/S1353-8020(15)00052-8/fulltext
  9. Hommel ALAJ, Krijthe JH, Darweesh S, Bloem BR. The association of comorbidity with Parkinson’s disease-related hospitalizations. Parkinsonism Relat Disord [Internet]. 2022 [cited 2023 Apr 12];104:123–8. Available from: https://www.prd-journal.com/article/S1353-8020(22)00332-7/fulltext
  10. Yu JRT, Walter BL. Addressing critical care gaps in inpatient Parkinson’s care - Minimizing the impact of comorbidities and developing new care delivery models. Parkinsonism Relat Disord [Internet]. 2022 [cited 2023 Apr 12];104:121–2. Available from: https://www.prd-journal.com/article/S1353-8020(22)00358-3/fulltext
  11. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med [Internet]. 1967;276(7):374–9. Available from: http://dx.doi.org/10.1056/NEJM196702162760703
  12. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa: Pharmacokinetics and Pharmacodynamics of Levodopa. Mov Disord [Internet]. 2008;23 Suppl 3(S3):S580-4. Available from: http://dx.doi.org/10.1002/mds.22037
  13. Aminoff MJ, Christine CW, Friedman JH, Chou KL, Lyons KE, Pahwa R, et al. Management of the hospitalized patient with Parkinson’s disease: current state of the field and need for guidelines. Parkinsonism Relat Disord [Internet]. 2011 [cited 2023 Apr 12];17(3):139–45. Available from: https://www.prd-journal.com/article/S1353-8020(10)00288-9/fulltext
  14. Nance MA, Boettcher L, Edinger G, Gardner J, Kitzmann R, Erickson LO, et al. Quality improvement in Parkinson’s disease: A successful program to enhance timely administration of levodopa in the hospital. J Parkinsons Dis [Internet]. 2020;10(4):1551–9. Available from: http://dx.doi.org/10.3233/JPD-202024
  15. Hou JG, Wu LJ, Moore S, Ward C, York M, Atassi F, et al. Assessment of appropriate medication administration for hospitalized patients with Parkinson’s disease. Parkinsonism Relat Disord [Internet]. 2012 [cited 2023 Apr 12];18(4):377–81. Available from: https://www.prd-journal.com/article/S1353-8020(11)00432-9/fulltext
  16. Richard G, Redmond A, Penugonda M, Bradley D. Parkinson’s disease medication prescribing and administration during unplanned hospital admissions. Mov Disord Clin Pract [Internet]. 2022;9(3):334–9. Available from: http://dx.doi.org/10.1002/mdc3.13408
  17. Yu J, Sonneborn C, Hogue O, Ghosh D, Brooks A, Liao J. Establishing a framework for quality of inpatient care for Parkinson’s disease: A study on inpatient medication administration. Parkinsonism and Related Disorders. Article in Press. 2023.
  18. Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, et al. Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract [Internet]. 2017;7(1):86–93. Available from: http://dx.doi.org/10.1212/CPJ.0000000000000316
  19. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease: Systematic Review of LED Reporting in PD. Mov Disord [Internet]. 2010;25(15):2649–53. Available from: http://dx.doi.org/10.1002/mds.23429
  20. Schade S, Mollenhauer B, Trenkwalder C. Levodopa equivalent dose conversion factors: An updated proposal including opicapone and safinamide: LED for opicapone and safinamide. Mov Disord Clin Pract [Internet]. 2020;7(3):343–5. Available from: http://dx.doi.org/10.1002/mdc3.12921
  21. Pepper PV, Goldstein MK. Postoperative complications in Parkinson’s disease. J Am Geriatr Soc [Internet]. 1999;47(8):967–72. Available from: http://dx.doi.org/10.1111/j.1532-5415.1999.tb01292.x
  22. Ahlskog JE. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls. Mayo Clin Proc [Internet]. 2014 [cited 2023 Apr 12];89(7):997–1003. Available from: https://www.mayoclinicproceedings.org/article/S0025-6196(14)00249-3/fulltext
  23. Lertxundi U, Isla A, Solinís MÁ, Echaburu SD, Hernandez R, Peral-Aguirregoitia J, et al. Medication errors in Parkinson’s disease inpatients in the Basque Country. Parkinsonism Relat Disord [Internet]. 2017 [cited 2023 Apr 12];36:57–62. Available from: https://www.prd-journal.com/article/S1353-8020(16)30521-1/fulltext
  24. Grissinger M. Delayed administration and contraindicated drugs place hospitalized Parkinson’s disease patients at risk. P T. 2018;43(1):10–39. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29290668
  25. Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson’s disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry [Internet]. 2015;86(3):324–30. Available from: http://dx.doi.org/10.1136/jnnp-2014-307822
  26. Lawson RA, McDonald C, Burn DJ. Defining delirium in idiopathic Parkinson’s disease: A systematic review. Parkinsonism Relat Disord [Internet]. 2019 [cited 2023 Apr 12];64:29–39. Available from: https://www.prd-journal.com/article/S1353-8020(18)30421-8/fulltext
  27. Golden WE, Lavender RC, Metzer WS. Acute postoperative confusion and hallucinations in Parkinson disease. Ann Intern Med [Internet]. 1989;111(3):218–22. Available from: http://dx.doi.org/10.7326/0003-4819-111-3-218 
  28. Oliver D, Daly F, Martin F, McMurdo M. Risk factors and risk assessment tools for falls in hospital in-patients: a systematic review. Age Ageing [Internet]. 2004 Mar 1;33(2):122–30. Available from: https://academic.oup.com/ageing/articlelookup/doi/10.1093/ageing/afh017
  29. Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RMA. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord [Internet]. 2011 [cited 2023 Apr 12];17(10):724–9. Available from: https://www.prd-journal.com/article/S1353-8020(11)00110-6/fulltext
  30. Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Myllylä VV. Orthostatic hypotension, balance and falls in Parkinson’s disease. Mov Disord [Internet]. 2009;24(5):745–51. Available from: http://dx.doi.org/10.1002/mds.22457
  31. Krauss MJ, Evanoff B, Hitcho E, Ngugi KE, Dunagan WC, Fischer I, et al. A case-control study of patient, medication, and care-related risk factors for inpatient falls. J Gen Intern Med [Internet]. 2005;20(2):116–22. Available from: http://dx.doi.org/10.1111/j.1525-1497.2005.40171.x
  32. Chang C-M, Chen M-J, Tsai C-Y, Ho L-H, Hsieh H-L, Chau Y-L, et al. Medical conditions and medications as risk factors of falls in the inpatient older people: a case-control study. Int J Geriatr Psychiatry [Internet]. 2011;26(6):602–7. Available from: http://dx.doi.org/10.1002/gps.2569
  33. Tanaka M, Suemaru K, Ikegawa Y, Tabuchi N, Araki H. Relationship between the risk of falling and drugs in an academic hospital. Yakugaku Zasshi [Internet]. 2008;128(9):1355–61. Available from: https://www.jstage.jst.go.jp/article/yakushi/128/9/128_9_1355/_article
  34. Martinez-Ramirez D, Giugni JC, Little CS, Chapman JP, Ahmed B, Monari E, et al. Missing dosages and neuroleptic usage may prolong length of stay in hospitalized Parkinson’s disease patients. PLoS One [Internet]. 2015;10(4):e0124356. Available from: http://dx.doi.org/10.1371/journal.pone.0124356
  35. Fagerlund K, Anderson LC, Gurvich O. Perioperative medication withholding in patients with Parkinson’s disease: a retrospective electronic health records review. Am J Nurs [Internet]. 2013 [cited 2023 Apr 12];113(1):26–35; quiz 36. Available from: https://journals.lww.com/00000446-201301000-00024
  36. Ciucci MR, Grant LM, Rajamanickam ESP, Hilby BL, Blue KV, Jones CA, et al. Early identification and treatment of communication and swallowing deficits in Parkinson disease. Semin Speech Lang [Internet]. 2013;34(3):185–202. Available from: http://dx.doi.org/10.1055/s-0033-1358367
  37. Martinez-Ramirez D, Almeida L, Giugni JC, Ahmed B, Higuchi M-A, Little CS, et al. Rate of aspiration pneumonia in hospitalized Parkinson’s disease patients: a cross-sectional study. BMC Neurol [Internet]. 2015;15(1):104. Available from: http://dx.doi.org/10.1186/s12883-015-0362-9
  38. Mueller MC, Jüptner U, Wuellner U, Wirz S, Türler A, Hirner A, et al. Parkinson’s disease influences the perioperative risk profile in surgery. Langenbecks Arch Surg [Internet]. 2009;394(3):511–5. Available from: http://dx.doi.org/10.1007/s00423-008-0404-5
  39. Berganzo K, Díez-Arrola B, Tijero B, Somme J, Lezcano E, Llorens V, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related? J Neurol [Internet]. 2013;260(7):1752–6. Available from: http://dx.doi.org/10.1007/s00415-013-6859-5
  40. Palma J-A, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?: Diagnostic accuracy of OH criteria in PD. Mov Disord [Internet]. 2015;30(5):639–45. Available from: http://dx.doi.org/10.1002/mds.26079
  41. Lance S, Travers J, Bourke D. Reducing medication errors for hospital inpatients with Parkinsonism. Intern Med J [Internet]. 2021;51(3):385–9. Available from: http://dx.doi.org/10.1111/imj.14782
  42. Aslam S, Simpson E, Baugh M, Shill H. Interventions to minimize complications in hospitalized patients with Parkinson disease. Neurol Clin Pract [Internet]. 2020;10(1):23–8. Available from: http://dx.doi.org/10.1212/CPJ.0000000000000709
  43. Medications to be avoided or used with caution in Parkinson’s disease [Internet]. [cited 2023 Mar 21]. Available from: https://www.apdaparkinson.org/wpcontent/uploads/2018/05/APDA-Meds_to_Avoid.pdf
  44. Chou KL, Zamudio J, Schmidt P, Price CC, Parashos SA, Bloem BR, et al. Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord [Internet]. 2011 [cited 2023 Apr 12];17(6):440–5. Available from: https://www.prd-journal.com/article/S1353-8020(11)00061-7/fulltext
  45. Mehta S, Vankleunen JP, Booth RE, Lotke PA, Lonner JH. Total knee arthroplasty in patients with Parkinson’s disease: impact of early postoperative neurologic intervention. Am J Orthop (Belle Mead NJ). 2008;37(10):513–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19081879
  46. Skelly R, Brown L, Fakis A, Kimber L, Downes C, Lindop F, et al. Does a specialist unit improve outcomes for hospitalized patients with Parkinson’s disease? Parkinsonism Relat Disord [Internet]. 2014 [cited 2023 Apr 12];20(11):1242–7. Available from: https://www.prd-journal.com/article/S1353-8020(14)00337-X/fulltext
  47. Lertxundi U, Isla A, Solinis MA, Domingo-Echaburu S, Hernandez R, García-Moncó JC. A proposal to prevent omissions and delays of antiparkinsonian drug administration in hospitals. Neurohospitalist [Internet]. 2015;5(2):53–4. Available from: http://dx.doi.org/10.1177/1941874414566986
  48. Ebersbach G, Ip CW, Klebe S, Koschel J, Lorenzl S, Schrader C, et al. Management of delirium in Parkinson’s disease. J Neural Transm (Vienna) [Internet]. 2019;126(7):905–12. Available from: http://dx.doi.org/10.1007/s00702-019-01980-7
  49. Burbridge BE, Wallace JK, Rajput A, McCulloch L. Doppler ultrasonographic examination of the leg veins of patients with Parkinson disease. J Psychiatry Neurosci. 1999;24(4):338–40.  Available from: http://www.ncbi.nlm.nih.gov/pubmed/10516801
  50. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol [Internet]. 2010;67(1):58–63. Available from: http://dx.doi.org/10.1001/archneurol.2009.294
  51. Roark C, Whicher S, Abosch A. Reversible neurological symptoms caused by diathermy in a patient with deep brain stimulators: case report: Case report. Neurosurgery [Internet]. 2008 [cited 2023 Apr 12];62(1):E256; discussion E256. Available from: https://journals.lww.com/00006123-200801000-00028
  52. Nutt JG, Anderson VC, Peacock JH, Hammerstad JP, Burchiel KJ. DBS and diathermy interaction induces severe CNS damage. Neurology [Internet]. 2001;56(10):1384–6. Available from: http://dx.doi.org/10.1212/wnl.56.10.1384
  53. Weaver J, Kim SJ, Lee MH, Torres A. Cutaneous electrosurgery in a patient with a deep brain stimulator. Dermatol Surg [Internet]. 1999;25(5):415–7. Available from: http://journals.lww.com/00042728-199905000-00016

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.